BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) saw its stock soar 7.83% in the after-hours trading session on Wednesday, following the company's impressive fourth-quarter results and an optimistic outlook for the full year 2025.
In the fourth quarter, BioMarin reported adjusted earnings of $0.92 per diluted share, significantly outperforming analysts' expectations of $0.53 per share. The company's revenue for the quarter stood at $747.3 million, surpassing the consensus estimate of $713.4 million.
The strong performance was driven by robust sales of BioMarin's key products, including VOXZOGO for achondroplasia, which saw a 42% year-over-year increase in revenue to $208 million during the quarter. The company's Enzyme Therapies portfolio also contributed significantly, with sales rising 9% year-over-year.
Looking ahead to 2025, BioMarin provided an optimistic outlook, projecting non-GAAP earnings per share in the range of $4.20 to $4.40 on revenue between $3.1 billion and $3.2 billion. This guidance surpassed analysts' expectations of $4.15 in earnings per share and $3.10 billion in revenue.
The company's solid performance and upbeat guidance reflect its strategic focus on expanding the global reach of its innovative therapies and advancing its robust pipeline of potential treatments for rare genetic disorders.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。